Pharma's new aims explain reform support

Why is Big Pharma such a willing supporter of healthcare reform? The industry has transformed from a business aiming to sell pills to the masses to one that markets very expensive treatments to small groups of sick people--and that changes everything, Forbes' Matthew Herper contends. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.